Feed

CLGN

CollPlant Biotechnologies Ltd.

CLGN · NASDAQ

$4.12 +2.74% (+$0.11)

1M +33.77%

Market Cap $5.34M

P/E Ratio -

Div. Yield -

ROE 160.28%

Piotroski F-Score Weak

1/9

Valuation

50 /100

Fair

P/S 13.73x

P/B 1.09x

P/E N/A

Growth

78 /100

Growing

Rev. growth 99.41%

Book val. growth 42.68%

EPS growth N/A

Profitability

0 /100

Weak

Gross margin 319.28%

Net margin 3,376.35%

Op. margin 3,329.05%

Quality

1 /100

Poor

ROIC 171.87%

ROE 160.28%

ROA 143.03%

Debt

60 /100

Moderate

Debt/Equity 0.54x

Current ratio 2.27x

Int. coverage -57.12x

Stability

26 /100

Unstable

Beta 0.74x

Rev. volatility 1,994.91%

EPS volatility 105.23%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about CLGN

Online

About the company

CollPlant Biotechnologies Ltd. (CLGN) is a biotechnology company operating in the field of regenerative medicine. The company focuses on the development and production of biological materials and collagen-based products for the treatment of various health conditions. CollPlant employs advanced technologies in creating bioinks and 3D printing for tissue and organ generation. The company emphasizes innovation and product development that could contribute to improvements in patient care. CollPlant Biotechnologies Ltd. (CLGN) shares could be an intriguing choice for investors interested in the biotechnology sector and regenerative medicine.

Sector

Healthcare

Industry

Biotechnology

CEO

Yehiel Tal

Employees

Headquarters

Rehovot

Upcoming events

02 DEC

Earnings

Upcoming earnings report

68d

⌘ K

StockBot Live

Market situation Europe

European stocks rebound as oil and bond yields retreat

Stoxx 600 +0.70% and DAX +0.60% rise as oil prices fall. US futures edge higher as 10-year yields ease to 5.1%.

Ask about this

StockBot knows 80,000+ stocks worldwide